Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the safety, tolerability and efficacy of intranasal ALN-RSV01 versus placebo, administered once daily for 5 days to a healthy male volunteers experimentally i...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alnylam Pharmaceuticals
NCT07220109 · Respiratory Syncytial Virus Infections
NCT07092865 · Respiratory Syncytial Virus Infections
NCT07239583 · Respiratory Syncytial Virus Infection, Respiratory Syncytial Virus Infections
NCT06534892 · Respiratory Syncytial Virus Infections
NCT06593210 · Vaccine Response Impaired, Respiratory Syncytial Virus Infections, and more
Alnylam Pharmaceuticals
Cambridge, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions